Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Some REMS May Still Require Review Extensions In New Model

Executive Summary

FDA’s proposed new review model may cut out the need for some deadline extensions, but if an extensive REMS is expected, the date still could be delayed.

You may also be interested in...

PDUFA Negotiations: FDA Wants To Be Able To Call "Time-Out" During Reviews

FDA has proposed a new application review model that would allow it to call a time-out, which could be used to resolve mid-cycle issues and, the agency argues, potentially bring more predictability to the process.

PDUFA Update: FDA Wants To Automatically Extend Complex Application Reviews

FDA wants industry to agree to a set of reasons that would automatically trigger a longer application review as part of the negotiations on reauthorizing the Prescription Drug User Fee Act.

ANDA Submissions Drop To Start FY2021

First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts